CERS

CerusA

Nasdaq / Health Care Equipment & Services

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$4.50

+75.8% vs current

Most likely

Base case

45%

Probability

Target price

$3.40

+32.8% vs current

B-

Bear case

25%

Probability

Target price

$1.80

-29.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

This is a better post-earnings setup than the April 29 baseline, but it is still not a high-conviction rerating memo. Primary filings confirmed a strong Q1 print, higher guidance, and materially improved loss performance, while the May 1 anchor price of $2.72 reflected a sharp immediate market reaction of roughly 34% versus the prior close. Follow-up coverage through May 1-2 was mostly constructive and included at least one upgrade, but low analyst coverage, mixed ratings, and lingering margin/regulatory questions argue for cautious monitoring language rather than an aggressive bullish call.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystQ1 beat and raised 2026 guidance need to hold through the post-print digestion windowHigh impact

Cerus reported Q1 2026 total revenue of $59.9 million, product revenue of $53.7 million, narrowed GAAP net loss to $1.6 million, and ended the quarter with cash and short-term investments of about $80.4 million cash equivalents plus $52.6 million short-term investments. Product revenue growth was driven by platelet kit volume and IFC demand, and management raised full-year product revenue guidance to $227 million-$231 million with IFC guidance to $22 million-$24 million. The next few weeks matter because the stock already reacted sharply and investors will test whether the stronger Q1 and higher guide are durable rather than one-quarter timing. [#8-K-2026-04-30] [#10-Q-2026-04-30]

2026-07-15eventMid-2026 INT200 FDA submission remains the next hard regulatory de-risking checkpointHigh impact

Company materials reviewed ahead of and around earnings continue to frame a mid-2026 FDA PMA submission for the next-generation INT200 illumination device as an important milestone, while Cerus also continues to flag regulatory timing risk around pipeline execution. A clean on-time filing would help validate the innovation leg of the thesis, but this remains a timing-sensitive medtech event rather than booked revenue. [#10-K-2026-03-02]

2026-12-31catalystIFC and platelet adoption must translate into sustained 2026 commercial scalingHigh impact

Management said Q1 strength was broad-based across U.S. IFC, North American platelet kits, and EMEA demand, with BCA execution and the renewed French EFS agreement improving visibility. The longer-duration upside case still depends on converting that demand into repeat volume, preserving positive adjusted EBITDA, and working through freight, tariff, FX, and supply-chain pressure that compressed product gross margin to 52% in Q1. [#10-Q-2026-04-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology